Molecular obesity, potency and other addictions in medicinal chemistry

Jan. 9, 2012 - PRLog -- SMi presents its 11th annual
Advances and Progress in Drug Design
20th & 21st February 2012, Copthorne Tara Hotel, London, UK

SMi’s Drug Design Conference will aim to address many of the challenging issues faced by the pharmaceutical industry in drug design. Key selected industry experts will provide you with timely and up-to-date information on many areas of drug design.

Leading speakers include:
Hit to lead with X-ray crystallography
Leveraging hits with crystal structure insight
Molecular design in team discovery
Synchrotron beamline upgrades for pharma
Kenton Longenecker, Protein Crystallographer, Structural Biology Department, Abbott.

Delivering impact from HTS - drawing on experiences from the Pfizer portfolio
This talk will provide specific examples in hit identification from HTS across the Pfizer portfolio, with a specific focus on:-
Evolving approaches to compound file & subset screening
Combining fragment screening & biophysics with small molecule HTS
Use of chemogenomic libraries & pre-competitive screening collaborations to identify novel probes & targets
John Mathias, Head of Medicinal Chemistry - Inflammation & Remodelling, Pfizer

Molecular obesity, potency and other addictions in medicinal chemistry
Review of the developability issues associated with compounds of high lipophilicity
Scientific and organisational reasons why we always tend towards such compounds
Resisting the urge to use such compounds
Mike Hann, Director of Structural Biology Europe, GlaxoSmithKline

Key note speakers include:
•   Suvit Thaisrivongs, Vice President, Discovery Chemistry, Pfizer
•   Mike Hann, Director of Structural Biology Europe, GSK
•   Herbert Nar, Director Structural Research, Boehringer Ingelheim
•   John Mathias, Head of the Pfizer HTS CoE, Head of Medicinal Chemistry - Inflammation & Remodelling, Pfizer
•   José Duca, Head of CADD, Novartis Institutes for BioMedical Research, Inc.
•   Gregor Macdonald, Head of Neuroscience Chemistry, Janssen Pharmaceuticals, Johnson & Johnson PRD

Further information can be found at http://www.smi-online.co.uk/2012drugdesign28.asp